Bayer (BAYN) Given a €123.00 Price Target at Baader Bank

Bayer (FRA:BAYN) has been assigned a €123.00 ($143.02) target price by equities research analysts at Baader Bank in a research note issued to investors on Friday. The firm currently has a “buy” rating on the healthcare company’s stock. Baader Bank’s price target would indicate a potential upside of 71.62% from the stock’s previous close.

BAYN has been the subject of a number of other research reports. Barclays set a €100.00 ($116.28) price target on shares of Bayer and gave the company a “buy” rating in a report on Thursday. Berenberg Bank set a €107.00 ($124.42) price target on shares of Bayer and gave the company a “buy” rating in a report on Thursday. HSBC set a €82.00 ($95.35) price target on shares of Bayer and gave the company a “neutral” rating in a report on Thursday. Deutsche Bank set a €127.00 ($147.67) price target on shares of Bayer and gave the company a “buy” rating in a report on Wednesday. Finally, BNP Paribas set a €90.00 ($104.65) price target on shares of Bayer and gave the company a “neutral” rating in a report on Tuesday. Ten analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Bayer presently has a consensus rating of “Buy” and an average price target of €101.36 ($117.86).

Shares of BAYN traded up €1.52 ($1.77) during midday trading on Friday, hitting €71.67 ($83.34). 1,695,210 shares of the company traded hands. Bayer has a 52 week low of €91.58 ($106.49) and a 52 week high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Article: Stock Symbols and CUSIP Explained

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply